Men with Metastatic Prostate Cancer Should Be Considered for Germline Genetic...
Men with metastatic prostate cancer should be considered for germline genetic testing of DNA repair genes, regardless of age or family history, according to a team of researchers from Memorial Sloan...
View ArticleMemorial Sloan Kettering Launches MSK Direct to Expand Access to World-Class...
In an effort to expand and streamline patient access to its high-quality cancer care, Memorial Sloan Kettering Cancer Center (MSK) has introduced MSK Direct, a unique program in which MSK collaborates...
View ArticleMemorial Sloan Kettering Researchers Engineer Micro-Pharmacies in CAR T Cells...
Dr. Hans Guido Wendel explains the untapped potential of CAR T cells to act as targeted delivery vehicles that can function as “micro-pharmacies” for precise therapeutic delivery. read more
View ArticleMSK Researchers Engineer Micro-Pharmacies in CAR T Cells to Treat B Cell...
There has been much recent excitement about immunotherapy and the use of genetically engineered chimeric antigen receptor (CAR) T cells. Historically, CAR T cell immunotherapy has aimed to boost the...
View ArticleMolecular Biologist Christine Mayr of Sloan Kettering Institute Honored with...
Molecular biologist Christine Mayr, MD, PhD, of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) is one of 12 2016 recipients of the prestigious National Institutes of Health (NIH)...
View ArticleMemorial Sloan Kettering Long Island Site Nearly Doubles
When Memorial Sloan Kettering opened its doors along Commack Road in 2002, eastern Long Islanders no longer needed to navigate congested roadways and train lines bound for Manhattan to receive...
View ArticleMemorial Sloan Kettering Debuts in Monmouth County
Nearly 20 years have passed since Memorial Sloan Kettering Cancer Center (MSK) first opened its doors in the Garden State. Since then, an explosion of knowledge and data has resulted in far better...
View ArticleMemorial Sloan Kettering and Hackensack Meridian Health Announce Cancer Care...
The Two Organizations Will Develop New Standards of Cancer Care, Open Joint Cancer Treatment Facilities read more
View ArticleMemorial Sloan Kettering Researchers Publish Roadmap to Precision Oncology
Researchers from Memorial Sloan Kettering Cancer Center (MSK) today published a seminal review of the rapidly evolving field of precision oncology, which allows doctors to recommend therapies based on...
View ArticleCAR T Cells More Powerful When Built With CRISPR, MSK Researchers Find
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have harnessed the power of CRISPR/Cas9 to create more-potent chimeric antigen receptor (CAR) T cells that enhance tumor rejection in mice....
View ArticleJeffrey A. Drebin, MD, PhD, Named Chairman of the Department of Surgery at...
Jeffrey A. Drebin, MD, PhD, has been named the new Chairman of the Department of Surgery at Memorial Sloan Kettering Cancer Center (MSK). Dr. Drebin brings to MSK decades of experience as a...
View ArticleMSK Expertise on Precision Medicine Highlighted in American Association for...
t. Research findings from Memorial Sloan Kettering Cancer Center (MSK) will be featured in this year’s American Association for Cancer Research (AACR) Annual Meeting press program. The AACR is the...
View ArticleMSK Expertise on Immunotherapy Highlighted in American Association for Cancer...
Jae Park, MD, a hematologic oncologist and assistant attending physician at Memorial Sloan Kettering Cancer Center (MSK), will present findings about the durability of CAR T cell therapy response in...
View ArticleWorld-Renowned Medical Oncologist Luis Diaz, MD, Named Head of the Division...
Luis A. Diaz, MD, has been named the Head of the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan Kettering (MSK). An accomplished physician, pioneering researcher, and...
View ArticleLandmark Analysis from Memorial Sloan Kettering Reveals Genomic Tumor...
Memorial Sloan Kettering (MSK) has reached a major milestone in bringing personalized treatments to more cancer patients. Michael Berger, PhD, Ahmet Zehir, PhD, and colleagues have reported an in-depth...
View ArticleMemorial Sloan Kettering Cancer Center Holds Topping Off Ceremony for David...
Memorial Sloan Kettering Cancer Center (MSK) executives, including longtime board member David Koch, along with construction workers and physicians will all gather today for a “topping off” ceremony to...
View ArticleNovel Sequencing Approach Seeks to Detect Cancers Genomic Alterations
Findings from an early study evaluating a sophisticated new genomic-sequencing approach that analyzes cell-free DNA (cfDNA) in the blood of people with advanced cancer will help inform development of a...
View ArticleResults Indicate That Larotrectinib Is Effective as the First Novel Targeted...
Larotrectinib (LOXO-101) has demonstrated consistent and durable antitumor activity in tropomyosin receptor kinase (TRK) fusion cancers across a wide range of patient ages and tumor types and was well...
View ArticlePhase III Trial of PARP Inhibitor Shows First Evidence of Improved Outcomes...
The first phase III trial of a PARP inhibitor used to treat breast cancer reported promising data at the annual meeting of the American Society of Clinical Oncology (ASCO). Mark Robson, MD, Clinic...
View ArticleReal-Time, Patient-Reported Symptom Monitoring Demonstrates an Overall...
Updated results of a clinical trial that launched in 2007 were presented today by Ethan Basch, MD, of Memorial Sloan Kettering Cancer Center (MSK) and UNC Lineberger Comprehensive Cancer Center, at the...
View Article